Indications
For the treatment of lameness, pain and mobility impairment of osteoarthritis (non-infectious arthrosis) and related musculoskeletal disorders by therapeutic activity on the underlying pathological processes (disease modifying osteoarthritis drug) in dogs.
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zydax
- Group
- Veterinary medicines
- Marketing authorisation holder
- Parnell Technologies (UK) Limited
- Status
- Application withdrawn
- EMA product number
- EMEA/V/C/004375
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic